Heteroaryl substituted triazole modulators of metabotropic...

Details Heteroaryl substituted triazole modulators of metabotropic... Heteroaryl substituted triazole modulators of metabotropic...

C - Chemistry, Metallurgy

07

D

C07D 401/04 (2006.01) A61K 31/4439 (2006.01) A61K 31/444 (2006.01) A61K 31/455 (2006.01) A61P 25/00 (2006.01) C07D 401/14 (2006.01)

Patent

CA 2469821

The disclosure relates to a compound which is selected from the group consisting of: 2-[1-(3-chlorophenyl)-1H-1,2,4-triazol-3-yl]pyridine; 3-(3-pyridin-2-yl-1H-1,2,4-triazol-1-yl)benzonitrile; 3 -(1-pyridin-2-yl-1H-1,2,4-triazol-3-yl)benzonitrile; 2-[3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl]pyridine; 3-(2-pyridin-2-yl-2H-1,2,3-triazol-4-yl)benzonitrile; 3-(1-pyridin-2-yl-1H-1,2,3-triazol-4-yl)benzonitrile; 3-(4-pyridin-2-yl-2H-1,2,3-triazol-2-yl)benzonitrile; 3-(4-pyridin-2-yl-1H-1,2,3-triazol-1-yl)benzonitrile; 2-[2-(3-chlorophenyl)-2H-1,2,3-triazol-4-yl]pyridine; 2-[1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]pyridine; 2-[2-(3,5-difluorophenyl)-2H-1,2,3-triazol-4-yl]pyridine; 2-[1-(3,5-difluorophenyl)-1H-1,2,3-triazol-4-yl]pyridine; 2-{2-[3-fluoro-5-(pyridin-2-yloxy)phenyl]-2H-1,2,3-triazol-4-yl}pyridine; 2-{1-[3-fluoro-5-(pyridin-2-yloxy)phenyl]-1H-1,2,3-triazol-4-yl}pyridine; 2-{4-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-2H-1,2,3-triazol-2-yl}pyridine; 2-{4-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-1,2,3-triazol-1-yl}pyridine; 2-[4-(3-cyanophenyl)-2H-1,2,3-triazol-2-yl]nicotinotrile; 3-[2-(5-nitropyridin-2-yl)-2H-1,2,3-triazol-4-yl]benzonitrile; 3-[1-(5-nitropyridin-2-yl)-1H-1,2,3-triazol-4-yl]benzonitrile; 3-[1-(3-nitropyridin-2-yl)-1H-1,2,3-triazol-4-yl]benzonitrile; 3-[2-(3 -nitropyridin-2-yl)-2H-1,2,3-triazol-4-yl]benzonitrile; 3-[1-(5-aminopyridin-2-yl)-1H-1,2,3-triazol-4-yl]benzonitrile hydrochloride; N-[3-(1-pyridin-2-yl-1H-1,2,3-triazol-4-yl)phenyl]pyridin-3-amine; N-[3-(2-pyridin-2-yl-2H-1,2,3-triazol-4-yl)phenyl]pyridin-3-amine; 3-(2-pyridin-2-yl-1H-1,2,3-triazol-4-yl)phenol; and 3-(2-pyridin-2-yl-2H-1,2,3-triazol-4-yl)phenol; or a pharmaceutically acceptable salt thereof which are metabotropic glutamate receptor - subtype 5("mGluR5") modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases. The disclosure further relates to a pharmaceutical composition containing said compounds and their uses thereof.

L'invention concerne des composés triazole, substitués directement, ou par formation de ponts, par un fragment hétéroaryle contenant N adjacent au point de jonction du hétéroaryle. Ces composés sont des modulateurs du sous-type 5 du récepteur métabotropique du glutamate ("mGluR5"), utiles pour le traitement de troubles psychiatriques ou de l'humeur, tels que, par exemple, la schizophrénie, l'anxiété, la dépression, le trouble bipolaire et le trouble panique, ainsi que le traitement de la douleur, de la maladie de Parkinson, du dysfonctionnement cognitif, de l'épilepsie, des troubles du rythme circadien, de la toxicomanie, de l'abus des médicaments, du retrait du médicament et d'autres troubles.

Affiliated with

Also associated with

Rating

Heteroaryl substituted triazole modulators of metabotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heteroaryl substituted triazole modulators of metabotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted triazole modulators of metabotropic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1355635